Clinical Trial

Quality of Life and Medical Care of Long-term Sarcoma Survivors in Germany (PROSa+)

Study acronym: PROSa+
Recruiting
View on ClinicalTrials.gov →
Summary
The study PROSa+ aims to assess patient-reported outcomes (PROs), patient-reported experiences (PREs), and the socioeconomic situation of long-term sarcoma survivors (≥ 5 years post-diagnosis, with or without active disease) in Germany. The mixed-methods research design includes a multicenter observational study with a cross-sectional questionnaire survey involving 1,600 participants (paper, online), qualitative interviews with up to 60 participants, and longitudinal analyses combining data from existing sarcoma registries and the previous PROSa study conducted between 2017 and 2020.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-22.
Status change: Not Yet Recruiting → Recruiting 2025-12-01
Trial Details
NCT Number NCT07148193
Lead Sponsor Technische Universität Dresden
Collaborators: German Sarcoma Foundation (DSS), German Cancer Research Center, Universitätsmedizin Mannheim, University Hospital, Essen, National Centre for Tumor Diseases Heidelberg
Conditions Sarcoma, Survivorship, Quality of Life (QOL), Medical Care
Enrollment 1,600 participants
Start Date 2025-11-28
Primary Completion 2027-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2025-12-08